|
Construction of a modified Arrhenius equation for predicting drug nitrosation in solid dosage form -Pub
|
|
4
|
909
|
April 21, 2026
|
|
Mutagenic and carcinogenic potency determinations for NDMA support the cumulative dose assumption underpinning the less-than-lifetime Threshold of Toxicological Concern -Pub
|
|
0
|
148
|
April 21, 2026
|
|
Kinetic reaction rates for nitrosamine formation using secondary amines pKa
|
|
3
|
306
|
April 21, 2026
|
|
About the amlodipine nitrosamines
|
|
3
|
200
|
April 21, 2026
|
|
EMA's Revision of the Acceptance Limit for N-Nitroso-N-desmethyl-diphenhydramine
|
|
4
|
433
|
April 20, 2026
|
|
Another Prazosin recall linked to N-nitroso-prazosin impurity C raises renewed concern for the finished product
|
|
8
|
545
|
April 20, 2026
|
|
Potential for Nitrosamines in Medical Device Combination Products - Letter to Industry(FDA)
|
|
4
|
171
|
April 20, 2026
|
|
Etelcalcetide Nitroamide – is this possible?
|
|
0
|
65
|
April 18, 2026
|
|
Maximum Daily Dose (MDD) of Cream Formulation
|
|
1
|
163
|
April 17, 2026
|
|
EMA - Appendix 1 - Update
|
|
79
|
8288
|
April 17, 2026
|
|
🇺🇸 FDA Workshop - Nitrosamine-driven Reformulation and Bioequivelance
|
|
1
|
226
|
April 17, 2026
|
|
Toxycologist ... not for you!
|
|
2
|
228
|
April 17, 2026
|
|
Nitrite in Amines
|
|
14
|
633
|
April 15, 2026
|
|
N-Nitroso meglumine
|
|
27
|
2187
|
April 15, 2026
|
|
Regarding the structural determination of N-nitrosyl abecacil
|
|
0
|
65
|
April 15, 2026
|
|
Stability Assessment of FDA Approved Varenicline Tartrate Products for Critical Quality Attributes – N-Nitroso Varenicline, Solid Form, and Dissolution-Pub
|
|
2
|
99
|
April 14, 2026
|
|
Testing of APIs for NDSRI
|
|
5
|
1281
|
April 12, 2026
|
|
FDA/CRCG Workshop on Bioequivalence Innovations for Generic Oral Products
|
|
0
|
98
|
April 11, 2026
|
|
Science-led approaches to nitrosamine qualification and safety assessment-webinar
|
|
0
|
117
|
April 11, 2026
|
|
AMES Test Study Designs for Nitrosamine Mutagenicity Testing -Pub
|
|
13
|
1567
|
April 9, 2026
|
|
Excipient Selection Strategies to Mitigate Nitrosamine Risks
|
|
0
|
193
|
April 8, 2026
|
|
Would EDTA disodium form nitrosamines?
|
|
13
|
4421
|
April 8, 2026
|
|
N-Nitrosamine Risk Management: From Toxicology to Targeted Analysis-Webinar
|
|
1
|
301
|
April 7, 2026
|
|
Society of Toxicology STO 2026 -Posters
|
|
1
|
103
|
April 7, 2026
|
|
Everthing you wanted to know about In vivo COMET assay -webinar
|
|
0
|
89
|
April 3, 2026
|
|
MDD for cream formulation
|
|
0
|
87
|
April 3, 2026
|
|
All are welcomed to participate in the Stakeholder Survey concerning a Potential USP Public Standard on Mutagenic Impurities
|
|
0
|
112
|
April 2, 2026
|
|
Question on the Method for Determining the Maximum Allowable Daily Usage of Terbinafine Ointment and Solution Formulations
|
|
2
|
150
|
April 2, 2026
|
|
🇸🇬 Singapore formalized Nitrosamine requirements for NDA and GDA Applications
|
|
0
|
126
|
April 1, 2026
|
|
FDA Announcement - Small Molecule Nitrosamines in Infusion Bags
|
|
17
|
2739
|
March 31, 2026
|